Tag Archives: Endo Pharmaceuticals

April, 2018

27 April
Endo to Acquire Specialty Pharmaceutical Company Somerset Therapeutics for $190 Million

DUBLIN, April 26, 2018 /PRNewswire/ — Endo International plc (NASDAQ: ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. marketplace, and the business of its India based affiliate Wintac Limited, which operates as Somerset Therapeutics’ contract …
Share

9 June
FDA Requests Removal of Opana ER for Risks Related to Abuse

Today, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is …
Share

19 May
Endo to Acquire Par Pharmaceutical for $8 Billion

In an effort to boost its generics business, Endo International PLC has agreed to buy Par Pharmaceutical Holdings Inc. for more than $8 billion. The company said that it has entered into a definitive agreement under which it will acquire privately-held Par from TPG in a transaction valued at $8.05 …
Share